AbbVie Inc vs Braze Inc — how do they compare? AbbVie Inc trades at $248.26 (market cap $441.94B), while Braze Inc trades at $27.52 (market cap $3.18B). The key difference: AbbVie Inc is far larger — about 139× Braze Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Braze Inc pays none. Which is the better fit depends on your goals.
| ABBV | BRZE | |
|---|---|---|
Market Cap | $441.94B | $3.18B |
Sector | Health | Technology |
52-Week High | $263.58 | $36.19 |
52-Week Low | $197.38 | $15.79 |
Enterprise Value | $506.19B | $2.87B |
Dividend Yield | 2.77% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Braze (BRZE) trades at $27.50, down 4.35% today but showing strong technical momentum with bullish moving averages. The company demonstrates impressive revenue growth, reaching $593.41 million in 2025 with 30% year-over-year expansion, though profitability remains elusive with a -15.51% net margin. Recent news highlights insider selling but also strong AI-driven customer engagement demand and four consecutive quarters of organic revenue acceleration.
The outlook remains positive with 96% analyst buy ratings and a $34.78 consensus target suggesting 26% upside. Key risks include persistent unprofitability despite growth and competitive pressures in the customer engagement software space. The stock's trajectory depends on continued revenue acceleration and eventual path to profitability.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →